Cargando…
Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
Many cancers overexpress one or more of the six human pro-survival BCL2 family proteins to evade apoptosis. To determine which BCL2 protein or proteins block apoptosis in different cancers, we computationally designed three-helix bundle protein inhibitors specific for each BCL2 pro-survival protein....
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127641/ https://www.ncbi.nlm.nih.gov/pubmed/27805565 http://dx.doi.org/10.7554/eLife.20352 |
_version_ | 1782470276664000512 |
---|---|
author | Berger, Stephanie Procko, Erik Margineantu, Daciana Lee, Erinna F Shen, Betty W Zelter, Alex Silva, Daniel-Adriano Chawla, Kusum Herold, Marco J Garnier, Jean-Marc Johnson, Richard MacCoss, Michael J Lessene, Guillaume Davis, Trisha N Stayton, Patrick S Stoddard, Barry L Fairlie, W Douglas Hockenbery, David M Baker, David |
author_facet | Berger, Stephanie Procko, Erik Margineantu, Daciana Lee, Erinna F Shen, Betty W Zelter, Alex Silva, Daniel-Adriano Chawla, Kusum Herold, Marco J Garnier, Jean-Marc Johnson, Richard MacCoss, Michael J Lessene, Guillaume Davis, Trisha N Stayton, Patrick S Stoddard, Barry L Fairlie, W Douglas Hockenbery, David M Baker, David |
author_sort | Berger, Stephanie |
collection | PubMed |
description | Many cancers overexpress one or more of the six human pro-survival BCL2 family proteins to evade apoptosis. To determine which BCL2 protein or proteins block apoptosis in different cancers, we computationally designed three-helix bundle protein inhibitors specific for each BCL2 pro-survival protein. Following in vitro optimization, each inhibitor binds its target with high picomolar to low nanomolar affinity and at least 300-fold specificity. Expression of the designed inhibitors in human cancer cell lines revealed unique dependencies on BCL2 proteins for survival which could not be inferred from other BCL2 profiling methods. Our results show that designed inhibitors can be generated for each member of a closely-knit protein family to probe the importance of specific protein-protein interactions in complex biological processes. DOI: http://dx.doi.org/10.7554/eLife.20352.001 |
format | Online Article Text |
id | pubmed-5127641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51276412016-11-30 Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer Berger, Stephanie Procko, Erik Margineantu, Daciana Lee, Erinna F Shen, Betty W Zelter, Alex Silva, Daniel-Adriano Chawla, Kusum Herold, Marco J Garnier, Jean-Marc Johnson, Richard MacCoss, Michael J Lessene, Guillaume Davis, Trisha N Stayton, Patrick S Stoddard, Barry L Fairlie, W Douglas Hockenbery, David M Baker, David eLife Cancer Biology Many cancers overexpress one or more of the six human pro-survival BCL2 family proteins to evade apoptosis. To determine which BCL2 protein or proteins block apoptosis in different cancers, we computationally designed three-helix bundle protein inhibitors specific for each BCL2 pro-survival protein. Following in vitro optimization, each inhibitor binds its target with high picomolar to low nanomolar affinity and at least 300-fold specificity. Expression of the designed inhibitors in human cancer cell lines revealed unique dependencies on BCL2 proteins for survival which could not be inferred from other BCL2 profiling methods. Our results show that designed inhibitors can be generated for each member of a closely-knit protein family to probe the importance of specific protein-protein interactions in complex biological processes. DOI: http://dx.doi.org/10.7554/eLife.20352.001 eLife Sciences Publications, Ltd 2016-11-02 /pmc/articles/PMC5127641/ /pubmed/27805565 http://dx.doi.org/10.7554/eLife.20352 Text en © 2016, Berger et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Berger, Stephanie Procko, Erik Margineantu, Daciana Lee, Erinna F Shen, Betty W Zelter, Alex Silva, Daniel-Adriano Chawla, Kusum Herold, Marco J Garnier, Jean-Marc Johnson, Richard MacCoss, Michael J Lessene, Guillaume Davis, Trisha N Stayton, Patrick S Stoddard, Barry L Fairlie, W Douglas Hockenbery, David M Baker, David Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer |
title | Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer |
title_full | Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer |
title_fullStr | Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer |
title_full_unstemmed | Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer |
title_short | Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer |
title_sort | computationally designed high specificity inhibitors delineate the roles of bcl2 family proteins in cancer |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127641/ https://www.ncbi.nlm.nih.gov/pubmed/27805565 http://dx.doi.org/10.7554/eLife.20352 |
work_keys_str_mv | AT bergerstephanie computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT prockoerik computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT margineantudaciana computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT leeerinnaf computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT shenbettyw computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT zelteralex computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT silvadanieladriano computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT chawlakusum computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT heroldmarcoj computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT garnierjeanmarc computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT johnsonrichard computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT maccossmichaelj computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT lesseneguillaume computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT davistrishan computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT staytonpatricks computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT stoddardbarryl computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT fairliewdouglas computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT hockenberydavidm computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer AT bakerdavid computationallydesignedhighspecificityinhibitorsdelineatetherolesofbcl2familyproteinsincancer |